Citatuzumabbogatox

Citatuzumab bogatox (VB6-845) is recombinant immunotoxin that composed of Fab fragment of humanized antibody targeting EpCAM and a modified cytotoxin bouganin. Citatuzumab bogatox binds to and selectively induces apoptosis in EpCAM-positive cell lines and shows good activity in EpCAM-positive human tumour xenograft models[1][2][3].

945228-49-9

VB6-845; Anti-Human EpCAM Recombinant Antibody Fab Fragment, 17-1A

12352203

Apoptosis

Apoptosis

Cancer-programmed cell death

Cancer

10 mM in DMSO

[Citatuzumabbogatox]

[1]Cizeau J, et al. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother. 2009 Jul-Aug;32 (6) :574-84. |[2]Eyvazi S, et al. Antibody Based EpCAM Targeted Therapy of Cancer, Review and Update. Curr Cancer Drug Targets. 2018;18 (9) :857-868. |[3]Bruce VJ, et al. Minimalist Antibodies and Mimetics: An Update and Recent Applications. Chembiochem. 2016 Oct 17;17 (20) :1892-1899.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P99282/

Inhibitory Antibodies

Phase 3